Cargando…
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
BACKGROUND: The impact of disease-modifying therapies on the efficacy to mount appropriate immune responses to COVID-19 vaccination in patients with multiple sclerosis (MS) is currently under investigation. OBJECTIVE: To characterize long-term humoral and cellular immunity in mRNA-COVID-19 MS vaccin...
Autores principales: | Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Magalashvili, David, Menascu, Shay, Warszawer, Yehuda, Dolev, Mark, Didikin, Maria, Harari, Gil, Sonis, Polina, Falb, Rina, Gurevich, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008178/ https://www.ncbi.nlm.nih.gov/pubmed/36933299 http://dx.doi.org/10.1016/j.msard.2023.104616 |
Ejemplares similares
-
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021) -
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021) -
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
por: Achiron, Anat, et al.
Publicado: (2022) -
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021) -
Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis
por: Menascu, Shay, et al.
Publicado: (2023)